Phathom Pharmaceuticals
OverviewSuggest Edit
Phathom Pharmaceuticals is a biopharmaceutical company focused on treating gastrointestinal diseases and disorders. The company offers Vonoprazan, a small molecule potassium-competitive acid blocker to treat gastroesophageal reflux disease, including erosive esophagitis, gastric and duodenal ulcer, and low dose aspirin-associated ulcer.
| Type | Public | |
| Founded | 2018 | |
| HQ | Buffalo Grove, IL, US | Map |
| Website | phathompharma.com |
Recent NewsAll News
- Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
- Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
- Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial
- Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences
Key People/Management at Phathom Pharmaceuticals
Terrie Curran
President, Chief Executive Officer & Director
Azmi Nabulsi
Chief Operating Officer
James Topper
Director
Joe Hand
Chief Administrative Officer
Todd Branning
Chief Financial Officer
Michael Cola
Director
Phathom Pharmaceuticals Office Locations
Phathom Pharmaceuticals has offices in Buffalo Grove, Florham Park and Menlo Park
Buffalo Grove, IL, US (HQ)
2150 E Lake Cook Rd #800Buffalo
Florham Park, NJ, US
100 Campus Dr #102
Menlo Park, CA, US
70 Willow Rd
Phathom Pharmaceuticals Financials and Metrics
Phathom Pharmaceuticals Revenue
| USD | |
|---|---|
Net income (Q2, 2020) | (21.1m) |
EBIT (Q2, 2020) | (20.0m) |
Market capitalization (14-Jan-2021) | 1.1b |
Closing stock price (14-Jan-2021) | 38.3 |
Cash (30-Jun-2020) | 247.3m |
EV | 876.3m |
Phathom Pharmaceuticals's current market capitalization is $1.1 b.
Annual
Annual
Phathom Pharmaceuticals Operating Metrics
Show all operating metricsPhathom Pharmaceuticals Cybersecurity Score
Phathom Pharmaceuticals Online and Social Media Presence
Phathom Pharmaceuticals's Trends
Phathom Pharmaceuticals News and Updates
December 16, 2020
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offer…
December 14, 2020
Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM (ET) Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM…
November 30, 2020
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial
Topline results expected in second half of 2021 Topline results expected in second half of 2021
November 27, 2020
Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences
FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will par…
November 19, 2020
Phathom Pharmaceuticals to Host Virtual Investor Day
FLORHAM PARK, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today confirmed it will host a virtual Investor Day on Dece…
September 09, 2020
Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference
FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will pa…
Phathom Pharmaceuticals Frequently Asked Questions
When was Phathom Pharmaceuticals founded?
Phathom Pharmaceuticals was founded in 2018.
Who are Phathom Pharmaceuticals key executives?
Phathom Pharmaceuticals's key executives are Terrie Curran, Azmi Nabulsi and James Topper.
How many employees does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 16 employees.
Who are Phathom Pharmaceuticals competitors?
Competitors of Phathom Pharmaceuticals include UNITY Biotechnology, Synthorx and Innovation Pharmaceuticals.
Where is Phathom Pharmaceuticals headquarters?
Phathom Pharmaceuticals headquarters is located at 2150 E Lake Cook Rd #800Buffalo, Buffalo Grove.
Where are Phathom Pharmaceuticals offices?
Phathom Pharmaceuticals has offices in Buffalo Grove, Florham Park and Menlo Park.
How many offices does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies